April 21, 2026: In this edition of Across the Consortium, we pause to recognize recent significant milestones and research accomplishments by our member institutions. From a prestigious NCI designation that will accelerate research advances from the lab to the clinic, to grant funding that will transform the way health care is delivered around the world, to research awards that will help early-career investigators launch new avenues for discovery, and due honor for those whose work has influenced international guidelines, there is much to celebrate from New Brunswick to Seattle and all points between. Read More

May 9, 2024:

Raymond J. Hohl, MD, PhD, was recently named chair of the Cancer Center Directors Committee for the Big Ten Cancer Research Consortium (Big Ten CRC). In this role, Dr. Hohl will help guide strategic priorities for the Big Ten CRC as the consortium enters its second decade. Dr. Hohl has been a member of the leadership committee since the consortium’s founding in 2013 and succeeds Howard Bailey, MD, director of the University of Wisconsin Carbone Cancer Center, as the committee chair. Read More

May 7, 2024:

The Big Ten Cancer Research Consortium (Big Ten CRC) recently appointed Oana Danciu, MD, as chair of the consortium’s steering committee. Dr. Danciu is associate director of clinical research at the University of Illinois Cancer Center, a breast oncologist at UI Health, and associate professor in the Division of Hematology and Oncology at the University of Illinois College of Medicine Chicago. She succeeds Vijaya Raj Bhatt, MBBS, MS, of the University of Nebraska Medical Center, as chair of the committee. Read More

December 3, 2023: 

Bringing the best ideas forward, pulling expertise across cancer centers, connecting through mentorships, and ensuring racial, ethnic and gender diversity in clinical trial participation are critical components of the Big Ten Cancer Research Consortium (Big Ten CRC), according to Chief Scientific Officer Monika Joshi, MD, MRCP, from the Penn State Cancer Institute, who spoke at the Big Ten CRC Summit 2023, which brought together more than 110 researchers, investigators, cancer centers, and industry participants. Read More

September 1, 2023: 

The Big Ten Cancer Research Consortium Diversity Committee talks with investigators, industry sponsors and patient advocates on how to work together to develop policies and strategic priorities for the Big Ten CRC that will foster growth, learning, and change that will create a more equitable environment for patients enrolled in clinical trials. Episode one: “Conversation with the Co-Chairs” is now available on Spotify and Amazon Music! Read More

September 6, 2023:

The Big Ten Cancer Research Consortium’s annual summit is being held at Big Ten Conference Headquarters in Chicago. The summit will take place on Saturday, September 30, 2023, and is hosted by the University of Wisconsin Carbone Cancer Center. Read More

August 31, 2023:

Members of the population science clinical trial working group had their work published in Cancer Epidemiology, Biomarkers & Prevention. The article is titled, “Current Approaches to Serving Catchment Areas in Cancer Centers: Insights from the Big Ten Cancer Research Consortium Population Science Working Group.” Read More

May 26, 2023: 

Big Ten CRC lung cancer study to be presented at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting in Chicago. Cynthia Wei, MD of the Indiana University School of Medicine will present on the Big Ten CRC study titled, “Phase II Study of Consolidation Immunotherapy with Nivolumab and Ipilimumab or Nivolumab alone following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC).” Read More

May 1, 2023: 

Big Ten Cancer Research Consortium (Big Ten CRC) will have an exhibitors booth at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting. Visit Booth #28115 to talk with our highly qualified staff about managing oncology/hematology multi-center clinical trials. Read More

March 27, 2023: 

Results from a Big Ten CRC bladder cancer study of concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder were published in the Journal for ImmunoTherapy of Cancer. Sponsor-investigator Monika Joshi, MD, of Penn State Cancer Institute led this single-arm, multi-institutional phase II study.
Read More